Ironwood Pharma (IRWD) Stock Forecast & Price Target

Compare

350 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IRWD Analyst Ratings

Hold

0 Buy

2 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Ironwood

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IRWD Stock 12 Month Forecast

Average Price Target

$3.40

▲(6.25% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Ironwood Pharma in the last 3 months. The average price target is $3.40 with a high forecast of $3.80 and a low forecast of $3.00. The average price target represents a 6.25% change from the last price of $3.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.5,3.523076923076923,3.546153846153846,3.569230769230769,3.5923076923076924,3.6153846153846154,3.6384615384615384,3.6615384615384614,3.6846153846153844,3.7076923076923074,3.730769230769231,3.753846153846154,3.776923076923077,{"y":3.8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.5,3.4923076923076923,3.4846153846153847,3.476923076923077,3.4692307692307693,3.4615384615384617,3.453846153846154,3.446153846153846,3.4384615384615382,3.4307692307692306,3.423076923076923,3.4153846153846152,3.4076923076923076,{"y":3.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.5,3.4615384615384617,3.423076923076923,3.3846153846153846,3.3461538461538463,3.3076923076923075,3.269230769230769,3.230769230769231,3.1923076923076925,3.1538461538461537,3.1153846153846154,3.0769230769230766,3.0384615384615383,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.62,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$3.80

Average Price Target$3.40

Lowest Price Target$3.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Chase Knickerbocker

Craig-Hallum

$1.7→$3.8

Hold

18.75%

Upside

Reiterated

11/26/25

Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (NASDAQ: TERN) and Ironwood Pharma (NASDAQ: IRWD)

Mohit Bansal

Wells Fargo

$1→$3

Hold

-6.25%

Downside

Reiterated

11/11/25

Ironwood Pharma (IRWD) Gets a Hold from Wells Fargo

Faisal Khurshid

Leerink Partners

Hold

-68.75%

Downside

Reiterated

08/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: 89bio (NASDAQ: ETNB), Relay Therapeutics (NASDAQ: RLAY) and Ironwood Pharma (NASDAQ: IRWD)

Amy Li

Jefferies

$0.7

Hold

-78.13%

Downside

Downgraded

04/15/25

Ironwood Pharma: Hold Rating Amid Uncertainty Over Apraglutide's Phase 3 Trial and Strategic Options

Jason Butler

Citizens JMP

Hold

―

Downgraded

04/14/25

Citizens JMP downgrades Ironwood Pharmaceuticals (IRWD) to Market PerformCitizens JMP analyst Jason Butler downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Market Outperform to Market Perform.

Amy Yi Li

UBS

$8→$0.7

Hold

-78.13%

Downside

Downgraded

04/14/25

Hold Rating on Ironwood Pharma Amid FDA Trial Requirements and Strategic Uncertainties

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chase Knickerbocker

Craig-Hallum

$1.7→$3.8

Hold

18.75%

Upside

Reiterated

11/26/25

Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (NASDAQ: TERN) and Ironwood Pharma (NASDAQ: IRWD)

Mohit Bansal

Wells Fargo

$1→$3

Hold

-6.25%

Downside

Reiterated

11/11/25

Ironwood Pharma (IRWD) Gets a Hold from Wells Fargo

Faisal Khurshid

Leerink Partners

Hold

-68.75%

Downside

Reiterated

08/07/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: 89bio (NASDAQ: ETNB), Relay Therapeutics (NASDAQ: RLAY) and Ironwood Pharma (NASDAQ: IRWD)

Amy Li

Jefferies

$0.7

Hold

-78.13%

Downside

Downgraded

04/15/25

Ironwood Pharma: Hold Rating Amid Uncertainty Over Apraglutide's Phase 3 Trial and Strategic Options

Jason Butler

Citizens JMP

Hold

―

Downgraded

04/14/25

Citizens JMP downgrades Ironwood Pharmaceuticals (IRWD) to Market PerformCitizens JMP analyst Jason Butler downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Market Outperform to Market Perform.

Amy Yi Li

UBS

$8→$0.7

Hold

-78.13%

Downside

Downgraded

04/14/25

Hold Rating on Ironwood Pharma Amid FDA Trial Requirements and Strategic Uncertainties

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

IRWD Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IRWD has received 0 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. IRWD average Analyst price target in the past 3 months is 3.40.

Each month's total comprises the sum of three months' worth of ratings.

IRWD Financial Forecast

IRWD Earnings Forecast

Next quarter’s earnings estimate for IRWD is $0.02 with a range of -$0.14 to $0.12. The previous quarter’s EPS was $0.23. IRWD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IRWD has Performed in-line its overall industry.

IRWD Sales Forecast

Next quarter’s sales forecast for IRWD is $62.43M with a range of $57.00M to $74.42M. The previous quarter’s sales results were $122.06M. IRWD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IRWD has Performed in-line its overall industry.

IRWD Stock Forecast FAQ

What is IRWD’s average 12-month price target, according to analysts?

Based on analyst ratings, Ironwood Pharma’s 12-month average price target is 3.40.

What is IRWD’s upside potential, based on the analysts’ average price target?

Ironwood Pharma has 6.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IRWD a Buy, Sell or Hold?

Ironwood Pharma has a consensus rating of Hold which is based on 0 buy ratings, 2 hold ratings and 0 sell ratings.

What is Ironwood Pharma’s price target?

The average price target for Ironwood Pharma is 3.40. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $3.80 ,the lowest forecast is $3.00. The average price target represents 6.25% Increase from the current price of $3.2.

What do analysts say about Ironwood Pharma?

Ironwood Pharma’s analyst rating consensus is a Hold. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of IRWD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ironwood Pharma (IRWD) Stock Forecast & Price Target

IRWD Analyst Ratings

IRWD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

IRWD Analyst Recommendation Trends

IRWD Financial Forecast

IRWD Earnings Forecast

IRWD Sales Forecast

IRWD Stock Forecast FAQ

Detailed List of Analyst Forecasts